🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Alice T. Shaw

Brigham and Women's Hospital

ORCID: 0000-0001-6337-1093

Also affiliated with Massachusetts General Hospital, Boston Biomedical (United States), Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile
4.0Author DataRank

Indexed papers

3in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5
Top 6%
4.0DataRank
Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Papers

Driven by 12 papers — median percentile 94. Top paper: “ALK-positive lung cancer: a moving target”.

ALK-positive lung cancer: a moving target

Nature Cancer(2023)10.1038/s43018-023-00515-0
N/A
4.3DataRank · unranked
176 citations

W. Marston Linehan, Alice T. Shaw, Jaime L. Schneider

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5
Top 6%
4.0DataRank
Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Response and Resistance to RAS Inhibition in Cancer

Cancer Discovery(2025)10.1158/2159-8290.cd-25-0349
N/A
1.0DataRank · unranked
44 citations

Julien Dilly, Alice T. Shaw, Andrew J. Aguirre, Richard Y. Ebright

Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib

Journal of Thoracic Oncology(2015)10.1097/jto.0000000000000455
N/A
0.769DataRank · unranked
168 citations

Carol A. Sherman, Kathryn Willoughby, Jennifer Logan, Elizabeth Kennedy, Priscilla K. Brastianos +3 more

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Nature(2023)10.1038/s41586-023-06303-1
N/A
0.753DataRank · unranked
150 citations

Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Sunwoo Oh +36 more

BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency

Cancer Research(2020)10.1158/0008-5472.can-20-1744
N/A
0.624DataRank · unranked
63 citations

Carla P. Concepcion, Caroline G. Fahey, Hasmik Keshishian, Arjun Bhutkar, Christine F. Brainson +23 more

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

npj Precision Oncology(2022)10.1038/s41698-022-00256-w
N/A
0.571DataRank · unranked
44 citations

Zihan Wei, Ranee Mehra, Alice T. Shaw, Christopher H. Lieu, Patrick M. Forde +24 more

Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9611
N/A
0.457DataRank · unranked
20 citations

Ted W. Johnson, Jochen K. Lennerz, Charlotte Lee, Harper Hubbeling, Beow Y. Yeap +4 more

Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study

Lung Cancer(2024)10.1016/j.lungcan.2024.108003
N/A
0.349DataRank · unranked
8 citations

Alissa J. Cooper, Bruce E. Johnson, Justin F. Gainor, W. Marston Linehan, Lecia V. Sequist +6 more

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms

Cancer Cell(2021)10.1016/j.ccell.2021.09.003
N/A
0DataRank · unranked
263 citations

Zofia Piotrowska, Patricia J. Hare, Huidong Chen, Hillary E. Mulvey, Aislinn Mayfield +23 more

Phase II Study of Cabozantinib in Patients With Bone Metastasis

The Oncologist(2022)10.1093/oncolo/oyac083
N/A
0DataRank · unranked
9 citations

Gregory A. Coté, M. Dror Michaelson, Lori J. Wirth, Justin F. Gainor, Alona Muzikansky +6 more

Clinicopathologic Characteristics of BRG1-Deficient NSCLC

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.01.002
N/A
0DataRank · unranked
150 citations

Alexa B. Schrock, Marina Kem, Nicholas A. Jessop, Jessica Lee, Siraj M. Ali +5 more